Histamine H3 receptor (antagonist / inverse agonist)

Assets acting on this target.

Class
Histamine H3 receptor antagonist / inverse agonist (wake-promoting)
Notes
original target text: histamine H3 | original target text: histamine H3 (inhibitor)

The histamine H3 receptor is a G protein-coupled receptor found mainly in the central nervous system, where it functions as a presynaptic autoreceptor and heteroreceptor. Activated by histamine, it normally suppresses further release of histamine as well as several other neurotransmitters, including norepinephrine, dopamine, acetylcholine, and serotonin. Blocking this receptor, either through antagonism or through inverse agonism (which additionally reduces the receptor's baseline signaling in the absence of histamine), removes this inhibitory brake and increases release of these wake- and attention-promoting chemical messengers. This mechanism is of interest for conditions marked by excessive sleepiness, impaired alertness, or cognitive slowing, such as narcolepsy, shift-work-related sleep disturbance, and attention or cognitive deficits seen in some neuropsychiatric and neurodegenerative disorders. Because the H3 receptor sits at a convergence point for multiple neurotransmitter systems, modulating it offers a way to promote wakefulness and cognitive engagement without directly stimulating any single pathway, such as the dopaminergic system, in isolation. The general pharmacological rationale is to restore or enhance daytime alertness and cognitive function by rebalancing histaminergic and related signaling in brain circuits that govern arousal.

By indication

Related mechanisms

Histamine H3 receptor (antagonist / inverse agonist) drugs compared

3 drugs, stage by indication
3 drugs acting on Histamine H3 receptor (antagonist / inverse agonist): developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
Pitolisant (Wakix)WakixBioprojet, Harmony Biosciences, Viatrissmall moleculeApprovedApproved in Narcolepsy; Phase 3 in Idiopathic Hypersomnia; Phase 3 in Prader-Willi Syndrome; Phase 2 in Myotonic Dystrophy Type 1
ALTO-203Alto Neurosciencesmall moleculePhase 2Phase 2 in Major Depressive Disorder
Pitolisant GRHarmony Biosciencessmall moleculeStage not recordedNot recorded

← all mechanisms